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Abstract
Background: Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-
term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment
compliance, and high costs. The development of new efficient regimens with shorter treatment durations for MDR-
TB will solve these issues and improve treatment outcomes.
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Methods: This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a
new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB.
The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20–24months.
The investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9
or 12months depending on time to sputum culture conversion. The primary outcome is the treatment success rate at
24months after treatment initiation. Secondary outcomes include time to sputum culture conversion on liquid and solid
media, proportions of sputum culture conversion on liquid media after 2 and 6months of treatment, treatment success
rate according to pyrazinamide resistance, and occurrence of adverse events grade 3 and above as evaluated by the
Common Terminology Criteria for Adverse Events. Based on an
α= 0.025 level of significance (one-sided test), a power of 80%, and a < 10% difference in treatment success rate between
the control and investigational arms (80% vs. 70%) when the anticipated actual success rate in the treatment group is
assumed to be 90%, the number of participants needed per arm to show non-inferiority of the investigational regimen was
calculated as 48. Additionally, assuming the proportion of fluoroquinolone-susceptible MDR-TB among participants as 50%,
and 5% loss to follow-up, the number of participants is calculated
as N/( 0.50 × 0.95), resulting in 102 persons per group (204 in total).
Discussion: This trial will reveal the effectiveness and safety of a new shorter regimen comprising four oral drugs, including
delamanid, linezolid, levofloxacin, and pyrazinamide, for the treatment of fluoroquinolone-sensitive MDR-TB. Results from
this trial will provide evidence for adopting a shorter and more convenient treatment regimen for MDR-TB.
Trial registration: ClincalTrials.gov, NCT02619994. Registered on 2 December 2015.
Keywords: Tuberculosis, Multidrug-resistant tuberculosis, Multicenter randomized trial, Non-inferiority, Shorter regimen,
Delamanid, Linezolid
Background
Multidrug-resistant tuberculosis (MDR-TB) is a disease
caused by Myocbacterium tuberculosis that is resistant to
at least isoniazid and rifampicin, the two most important
anti-TB drugs. It accounts for 3.5% of newly diagnosed
TB patients and 20.5% of retreatment TB patients globally.
In 2016, approximately 490,000 people were diagnosed
with MDR-TB, approximately 9% of whom had extensively
drug-resistant tuberculosis (XDR-TB), which is resistant
to isoniazid and rifampicin plus any fluoroquinolone and
at least one of three injectable second-line drugs [1, 2].
In South Korea, 852 new patients with MDR-TB were
notified in 2016, and this number has been relatively
unchanged in recent years [3, 4].
Traditionally, in order to treat MDR-TB, second-line
anti-TB drugs must be used for at least 20months. Add-
itionally, an injectable drug is needed for the first 8months
of treatment [5]. Despite the long duration of treatment, the
treatment success rate remains unsatisfactory. According to
the latest World Health Organization (WHO) report, the
proportion of MDR-TB/rifampicin-resistant TB (RR-TB)
patients who successfully completed treatment (i.e., were
cured or completed treatment) was as low as 54% [2]. One
important reason for disappointing treatment outcomes is
non-adherence to treatment; 15% of MDR-TB patients were
lost to follow-up before treatment completion [2].
Patients with MDR-TB frequently experience adverse
events (AEs) over the treatment course. One report showed
that 57.3% of 5346 patients experienced at least one adverse
drug event (ADE) including gastrointestinal disorders
(32.1%), ototoxicity (14.6%), and psychiatric disorders
(13.2%) [6]. Additionally, among 1519 patients who devel-
oped ADEs with available data on MDR-TB therapy, 70.4%
required a change of MDR-TB treatment [6]. Another
report from a Korean TB cohort showed that major ADEs
were more frequent in patients being treated with second-
line regimens (16%) compared with first-line regimens
(2.5%) [7].
Considering all of these issues, a shorter and more
convenient regimen for MDR-TB treatment is urgently
needed. Fortunately, repurposed anti-TB drugs including
linezolid or newly developed drugs including delamanid
and bedaquiline are available for patients with MDR-TB
[8–11]. Recently, TB research has focused on identifying
the optimal combination of existing and new anti-TB
drugs to improve treatment outcomes as well as shorten
treatment duration [12].
We hypothesize that a new regimen consisting of fully oral
medications including delamanid, linezolid, levofloxacin,
and pyrazinamide for 9–12months is non-inferior to the
conventional regimen including second-line anti-TB drugs




This randomized controlled trial is being conducted at
12 referral hospitals in South Korea. The flow diagram
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for the trial is shown in Fig. 1. Patients with pulmonary TB
satisfying the inclusion criteria are competitively enrolled
by the investigators in the 12 participating hospitals.
Design
This is a phase II/III, multicenter, randomized,
open-label clinical trial with two arms. Adult pulmonary
TB patients with confirmed MDR-TB or RR-TB are eli-
gible. Once eligibility is confirmed and the participant
consents to participate, he/she will be randomly
assigned to one of the two groups (arm 1 or 2) at a 1:1
ratio.
Arm 1 (control arm)
Treatment will be performed according to the 2014
Korean guidelines for the treatment of tuberculosis [13, 14]
and the 2014 WHO guidelines [15] (Table 1). Treatment
principles include the following: (1) intensive phase regi-
men comprising four effective second-line anti-TB drugs
(including an injectable) and pyrazinamide should be used
for a minimum of 8months duration; (2) at least five active
drugs should be used, appropriately selected based on drug
susceptibility testing results (e.g., pyrazinamide, an inject-
able, a fluoroquinolone, prothionamide, and cycloserine);
(3) efforts should always be made to use a fluoroquinolone
(preferentially levofloxacin or moxifloxacin); (4) prothiona-
mide or cycloserine should be used preferentially, but when
it is not possible, p-aminosalicylic acid (PAS) can be used;
(5) the recommended length of the intensive phase includ-
ing injectable is 8months and the total treatment duration
is 20–24months.
Arm 2 (investigational arm)
The regimen consists of fully oral medications including
delamanid, linezolid, levofloxacin, and pyrazinamide for
9–12 months (Table 2). Treatment principles include the
following: (1) delamanid will be used for the entire treat-
ment period unless it must be stopped for reasons such as
AEs; (2) linezolid is started at a dose of 600mg/day for 2
months and reduced to 300mg/day in the third month of
treatment or earlier when AEs occur; (3) levofloxacin can
be substituted with moxifloxacin in case of AE develop-
ment, and this substitution will not be considered as a drug
change since both are fluoroquinolones of similar potency;
(4) pyrazinamide can be continued even if pyrazinamide
resistance is discovered on the phenotypic drugs suscepti-
bility testing after commencing treatment [15]; (5) total
treatment duration is 9months (40 weeks) when sputum
culture conversion occurs within 3months of treatment or
12months (52weeks) when sputum culture conversion
occurs between 3 and 6months of treatment.
The study timeline is shown in Tables 3 and 4. Treatment
adherence is evaluated during every visit by a research
nurse who keeps track of packages and returned drugs. If
scheduled visits are delayed or cancelled, the study team
will try to contact participants as soon as possible by
telephone.
Outcomes
The primary outcome is treatment success rate at
24 months after the initiation of treatment. The secondary
outcomes include time to sputum culture conversion to
negative on liquid and solid culture media, proportion
Fig. 1 The flow diagram of the trial
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of participants with sputum culture conversion at 2 and
6months of treatment on liquid culture medium, occur-
rence of AEs grade 3 and above, proportion of participants
with treatment success at the end of treatment, proportion
of participants reverting to positive sputum culture
after the end of treatment, treatment success rates ac-
cording to pyrazinamide resistance, proportion of
deaths, and time to death.
Definitions
Culture conversion and reversion
We define sputum culture conversion as two consecutive
negative sputum cultures taken at least 4 weeks apart. The
date of culture conversion is defined as the date of the ini-
tial negative culture. Culture conversion was also defined
as a patient who could not expectorate sputum after one
negative sputum culture. When two or more positive cul-
tures occur again after negative conversion, it is regarded
as reversion.
Treatment outcomes
We define treatment outcomes with reference to 2014
WHO Guidelines [15] (Table 5). For the investigational
group, 6months will be considered as the intensive phase.
Furthermore, “stopping” of drugs during treatment will
not be considered as “drug change.”
Both “cured” and “treatment completed” are defined
as treatment success. Treatment failure, death, loss to
follow-up, transfer out, and relapse are excluded from
treatment success.
Eligibility criteria
Participants with pulmonary TB satisfying the inclusion
criteria are competitively enrolled by investigators in both
outpatient and inpatient settings in the 12 participating
hospitals. Inclusion criteria are as follows: men and women
aged ≥ 19 and ≤ 85 years, with confirmed MDR-TB by
phenotypic or genotypic drug susceptibility tests or
RR-TB by genotypic tests such as Xpert® Mycobacterium
tuberculosis (MTB)/resistance to rifampin (RIF) assay
(Cepheid, Sunnyvale, CA, USA) regardless of being posi-
tive for sputum acid-fast bacilli smear, and use of current
anti-TB regimen with second-line drugs for ≤ 14 days at
the time of enrollment.
We will exclude patients with any fluoroquinolone-re-
sistant MDR-TB, XDR-TB patients, and pregnant women
or women of childbearing age unwilling to use proper
contraceptives. Additionally, any of the following factors
will lead to exclusion: (1) medical history of galactose
intolerance, Lapp lactase deficiency, or glucose-galactose
malabsorption; (2) history of optic neuropathy or periph-
eral neuropathy; and (3) the need for ongoing use of
prohibited drugs while on study drugs. Additionally, we
will exclude patients having any of the following test
results: (1) absolute neutrophil count < 2.0 × 103/μL, (2)
white blood cell count < 3.0 × 103/μL, (3) hemoglobin
< 7.0 g/dL, (4) serum creatinine > 2.0mg/dL, (5) aspartate
aminotransferase > 100 IU/L, (6) alanine aminotransferase
> 100 IU/L, (7) total bilirubin > 2.0 mg/dL, (8) albumin
< 2.8 g/dL, and (9) prolonged QT interval (QTc corrected
by Fridericia’s formula, QTcF > 500ms). Finally, patients
who have a history of hypersensitivity reaction to the
study drugs will be excluded.
Randomization
We assign participants to the study arm based on a 1:1
randomization ratio. The randomization sequence was
generated by a trial statistician using a block randomization
method stratified by the presence/absence of cavitation
on baseline chest radiographs and the presence/absence
of baseline diabetes mellitus. A web-based randomization
system is operated remotely at the Medical Research
Collaborating Center (MRCC) in Seoul National University
Hospital. Access to and management of randomization
information will be carried out independently from the
tasks of the clinical investigator or trial sponsor.
Justification of sample size
The hypothesis of this study is that the treatment success
rate at 24months of treatment for MDR-TB using the
new regimen including new anti-TB drugs will not be
inferior to that of conventional treatment regimens
(non-inferiority test).
Hypotheses for sample size calculation
The sample size calculation hypotheses are defined as
follows.
H0 (null hypothesis): PT − PC ≤ δ (new regimen treatment
success rate after 24 months of treatment is inferior to
conventional treatment success rate).
H1 (alternative hypothesis): PT − PC > δ (new regimen
treatment success rate at 24 months is not inferior to
conventional treatment success rate).
Assumptions
Based on the results of our previous study, we presume
the 24-month treatment success rate of the control arm
as 80% [16, 17].
Based on an α = 0.025 level of significance (one-sided
test), a power of 80%, < 10% difference in treatment success
rates between the control and investigational arms (80% vs.
70%) when we anticipate that the actual success rate in the
treatment group will be 90%, the sample size per arm to
show non-inferiority of the investigational regimen was
calculated to be 48. Additionally, reflecting (1) propor-
tion of fluoroquinolone-susceptible MDR-TB among
participants as 50%, and (2) anticipating 5% loss to
follow-up, the final number of participants is calculated
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as N/(0.50 × 0.95), resulting in 102 persons/group (204
in total).
If a participant withdraws for any reason within 2 weeks
after enrollment, that participant will be replaced. Consid-
ering the number of replaced participants, the enrollment
accrual ceiling is 220 persons maximum.
Statistical analysis
The results of this trial for efficacy outcomes will be
analyzed based on both modified intention-to-treat
(mITT) and per protocol (PP) approaches with a primary
consideration for mITT results. A PP analysis will be per-
formed secondarily. A safety analysis will be performed
based on the safety group. The mITT group will include
participants who are randomized after satisfying eligibility
criteria and receive study drugs at least one time. The PP
group will include participants who satisfy the following
conditions among the mITT group: (1) those who com-
pleted > 80% of the planned treatment, (2) those who
completed the clinical trial according to the protocol. The
safety analysis group will include participants who receive
study drugs at least once.
Efficacy outcomes
Comparisons will be performed using two-sided tests with
a statistical significance level of 5% unless stated otherwise.
Analysis of primary outcome
For the primary outcome of this trial, we will describe
the treatment success rate at 24 months of the control
arm and the investigational arm with a two-sided 95%
confidence interval. To test for non-inferiority of the
investigational arm, when the lower limit of the one-sided
97.5% confidence interval of the difference (PT − PC)
between investigational and control arms is larger than
the non-inferiority margin of − 10%, it will be concluded
that the treatment success rate of the investigational arm
shows non-inferiority to the treatment success rate of the
control arm.
Analysis of secondary outcomes
The analysis of secondary outcomes will be described as
exploratory outcomes. To determine whether time to
sputum culture conversion after treatment start is statis-
tically different between the control and investigational
arms, the median time will be estimated in each group
using the Kaplan-Meier method, and the difference in
the distribution of time to culture conversion of the two
arms will be compared using the log-rank test.
To test whether there is a statistical difference in propor-
tion of sputum culture conversion (liquid and solid culture
media) at 2months or 6 months of treatment, treatment
Table 1 Dose and schedule of anti-TB drugs recommended by the Korean national guidelines [37]
Drug Dose Usage
Usual dose Maximal dose
Pyrazinamide 1000mg (< 50 kg)
1500mg (50–70 kg)
2000mg (> 70 kg)





15 mg/kg (< 50 years)
10 mg/kg (≥ 50 years)
1000mg (< 50 years)
750 mg (≥ 50 years)
Once, intramuscularly
Cycloserine 500 mg (< 50 kg)
750 mg (50–70 kg)
750–1000mg (> 70 kg)
1000mg Once or divide in two,
before or after meal
Prothionamide 500mg (< 50 kg)
750 mg (50–70 kg)
750–1000mg (> 70 kg)
1000mg Once or divide in two, after meal
p-aminosalicylic acid 150 mg/kg 12 g Divide in two, after meal
Levofloxacin 750 mg (< 50 kg)
1000mg (50–70 kg)
1000mg Once, before or after meal
Moxifloxacin 400 mg 400mg Once, before or after meal
Table 2 Dose and schedule of anti-TB drugs of investigational
arm
Drug Dose Usage
Linezolid 600 mg/day for initial 2 months,
then 300mg/day
Once
Delamanid 200mg/day Divide in two, together
with meal




Pyrazinamide 1000mg (< 50 kg)
1500mg (50–70 kg)
2000mg (> 70 kg)
Once
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success at the end of treatment, reverting to positive spu-
tum culture after the end of treatment, treatment success
according to pyrazinamide resistance, and death between
the control and investigational arms, proportions of each
arm will be summarized by frequency and percentage and
these will be compared using the chi-square test and Fish-
er’s exact test. The median time to death after treatment
start will be estimated in each group using Kaplan-Meier
method, and the difference in the distribution of time to
death of the two arms will be compared using the
log-rank test.
Safety assessment
All AEs and serious AEs (SAEs) according to the Common
Terminology Criteria for Adverse Events (CTCAE),
regardless of severity, seriousness, or relationship to the
study drug, will be collected and documented.
We will summarize all AEs and SAEs, AE frequency
and percentage, and 95% confidence intervals. Addition-
ally, we will summarize and evaluate the occurrence rate
of AEs in relationship to the study drug and severity.
The occurrence rate of ADEs (CTCAE grades 3 and 4)
of the two arms and the proportion per type of toxicity
will be compared using the chi-square test or Fisher’s
exact test.
Stratified analysis
Primary and secondary outcomes will be analyzed separately
in participants with sputum smear-positive and smear-
negative pulmonary TB.
Table 3 Study timeline for control arm
Screening Baseline
visita
Treatment End of treatmentg
(End of study)










Physical exam X X X X X X X X
Neurological exam X
Sputum AFB smear X e X e X X X X X X X
TB culture (solid) X e X e X X X X X X X
TB culture (liquid) X e X e X X X X X X X
Genotypic DST If available
Phenotypic DSTb With first/reverted cultured Mycobacterium tuberculosis
CXR X e X e X h X h X X X X X
Chemistry, electrolytes X e X e X X X X X X X
Complete blood count X e X e X X X X X X X
ECG X e
Urine HCGc X X
HIV, HBVd X e
Optic test X
Compliance of drug intake X X X X X X X
Adverse drug reaction X X X X X X X
Other medicationf X X X X X X X X X
AFB acid-fast bacilli, CXR chest x-ray, DST drug susceptibility testing, ECG electrocardiogram, HBV hepatitis B virus, HCG human chorionic gonadotropin, HIV human
immunodeficiency virus, NA not applicable, TB tuberculosis
aAdministration of anti-TB regimen can begin at baseline visit since drug-resistant TB must be treated immediately
bDrug susceptibility test for isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, levofloxacin, moxifloxacin,
prothionamide, cycloserine, and p-aminosalicylic acid (can be omitted for patients with results already provided)
cOnly in females of childbearing potential (blood HCG test results are available)
dStudy drugs can be administered before obtaining the results since eligibility is not determined by these results
eCan be omitted if previous tests except ECG were done within 4 weeks. In case of ECG, within 1 week
fCheck prohibited drugs for exclusion criteria at screening visit and check immunosuppressants including steroids after enrollment
gEnd of treatment visit will be determined by the time of culture conversion
hCan be omitted if previous test was done within 2 weeks
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Data collection and management
This study will use a web-based electronic case report
form (e-CRF) with Pharmaco-epidemiology and Clinical
Trial Application X (PhactaX). PhactaX has been devel-
oped by the MRCC in collaboration with an outsourced
contractor. PhactaX is based on Java and Oracle databases
and complies with international standards and regulations.
The e-CRF designed for this study used dummy variables
for user acceptance testing to confirm its validity.
During the study, medical personnel not participating in
this study will monitor this trial. Monitors will visit sites
to monitor all aspects of the study including adherence to
the protocol and Good Clinical Practice, protection of
study participants, and data accuracy of the study.
Supervision of the trial
A Data and Safety Monitoring Board (DSMB) composed
of two respiratory specialists who have experience with
treating MDR-TB patients and one statistician from an-
other institute with no conflict of interests will be formed.
The DSMB will review data every 3months during the
trial and may provide recommendations such as change,
continuation, or stopping of protocols to the investigators
based on the results.
Confidentiality
Collection and operation of participants’ personal infor-
mation will be limited to only information necessary for
efficacy, safety, and tolerability evaluation of study drugs.
Table 4 Study timeline for investigational arm
Screening Baseline
visita
Treatment End of treatment
(EOT)g
EOT to end of study
Weeks (w) –2 w ~ –1 d 0 1 w 2 w 4 w 8 w 12 w ~ (every 4w) 40 w ~ 52 w ~ 24months
(every 2 months)




Physical exam X X X X X X X g
Neurological exam X X X X X X X g
Sputum AFB smear X e X e X X X X X X X
TB culture (solid) X e X e X X X X X X X
TB culture (liquid) X e X e X X X X X X X
Genotypic DST If available
Phenotypic DSTb With first/reverted cultured Mycobacterium tuberculosis
Resistance test If needed (for linezolid, delamanid)
CXR X e X e X h X h X X X X X
Chemistry, electrolytes X e X e X X X X X X g
Complete blood count X e X e X X X X X X g
ECG X e X e X X X X X X g
Urine HCGc X X X X X X X X g
HIV, HBVd X e
Optic test X X X X X X X X g
Compliance of drug intake X X X X X X g
Adverse drug reaction X X X X X X g
Other medicationf X X X X X X X X g
AFB acid-fast bacilli, CXR chest x-ray, DST drug susceptibility testing, ECG electrocardiogram, HBV hepatitis B virus, HCG human chorionic gonadotropin, HIV human
immunodeficiency virus, NA not applicable, TB tuberculosis
aAdministration of anti-TB regimen can begin at baseline visit since drug-resistant TB must be treated immediately
bDrug susceptibility test for isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, amikacin, capreomycin, ofloxacin, levofloxacin, moxifloxacin,
prothionamide, cycloserine, and p-aminosalicylic acid (can be omitted for patients with results already provided)
cOnly in females of childbearing potential (blood HCG test results are available)
dStudy drugs can be administered before obtaining the results since eligibility is not determined by these results
eCan be omitted if previous tests except ECG were done within 4 weeks. In case of ECG, within 1 week
fCheck prohibited drugs for exclusion criteria at screening visit and check immunosuppressants including steroids after enrollment
gEnd of study visit will be determined by the time of culture conversion. Omit test after end of treatment visit
hCan be omitted if previous test was done within 2 weeks
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Such data will be collected and processed taking precau-
tions for compliance with laws on privacy protection and
guaranteeing of confidentiality. Paper files containing par-
ticipants’ data (including personally identifiable informa-
tion and copies of signed consent forms) will be securely
stored in a locked office on sites in locked filing cabinets.
Digital files containing participants’ data will be stored in
password-protected files on university-maintained servers.
Access to study files will be restricted to authorized
personnel only.
The items in the present study protocol comply with
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist (see Additional file 1).
Discussion
Several trials have been conducted with the aim of over-
coming difficulties in MDR-TB treatment. In 2010, a
relapse-free cure rate of 87.9% among 206 patients treated
with a 9-month regimen of gatifloxacin, clofazimine,
ethambutol, and pyrazinamide throughout the treatment
period supplemented with prothionamide, kanamycin,
and high-dose isoniazid during an intensive phase of 4
months was reported [18]. This result was largely repli-
cated in subsequent studies [19], and WHO endorsed a
shorter course regimen in 2016 [5].
However, this shorter regimen includes too many
drugs, as many as seven, and still includes an injectable
(kanamycin) for the first 4–6 months. Additionally, the
number of candidates for this shorter treatment, i.e.,
patients without resistance to all drugs included in the
regimen, could be limited. In European MDR-TB cohorts,
on average, only 7.8% were eligible for this shortened regi-
men [20]. Reports from other areas, including Singapore,
Brazil, Pakistan, and South Korea, assume eligibility for
the shorter regimen ranged from 30 to 55% [21–24].
Fortunately, repurposed anti-TB drugs including linezo-
lid or newly developed drugs including delamanid and
bedaquiline have been introduced for MDR-TB treatment.
A meta-analysis of 12 non-randomized studies showed
that 82% of patients treated with a linezolid-containing
regimen demonstrated favorable treatment outcomes [8].
Additionally, a randomized trial in which linezolid was
used for XDR-TB patients reported a 6-month culture
conversion rate of 87% and a treatment success rate with-
out relapse at 1 year follow-up of 71% [9, 25]. Delamanid,
a nitro-dihydro-imidazooxazole derivative, demonstrated
activity against MDR-TB as measured by increased spu-
tum culture conversion rate in a randomized, placebo-
controlled trial. Patients who received a background drug
regimen plus 100mg or 200mg of delamanid twice daily
had sputum culture conversion rates in liquid broth at
2 months of 45.4% and 41.9%, respectively, as compared
with 29.6% of patients who received a background drug
regimen plus placebo [10]. In a subsequent observa-
tional extension trial for 24 months, favorable outcomes
were observed in 74.5% of patients who received delamanid
for ≥ 6months compared with 55% of patients who received
delamanid for ≤ 2months [26]. Bedaquiline, a diarylquino-
line, showed efficacy in a randomized phase II trial; it in-
creased the culture conversion rate to 62% and the cure rate
to 58% at 120weeks as compared with the placebo group
(44% and 32%, respectively) [27]. Additionally, bedaquiline-
containing regimens achieved high conversion and treat-
ment success rates in a different large retrospective
observational study [28].
Based on the proven efficacy of these new anti-TB
drugs, several clinical trials using 6–12-month regimens
for MDR-TB treatment without an injectable are being
tested. First, the STREAM Stage 2 trial (NCT02409290,
phase III) is comparing the effectiveness of 6- and
9-month bedaquiline-containing regimens against the
conventional WHO regimen and a 9-months regimen
including an injectable. Another phase III trial (NeXT,
NCT02454205) is testing 6- or 9-month treatments
containing bedaquiline, linezolid, levofloxacin, ethion-
amide/high-dose isoniazid, and pyrazinamide.
Table 5 Definitions of treatment outcomes for patients who are
drug-resistant
Cured Treatment completed as recommended by the
national policy without evidence of failure AND
culture conversion after the intensive phasea
Treatment completed Treatment completed as recommended by the
national policy without evidence of failure BUT
no record of culture conversion after the
intensive phasea
Treatment failed Treatment terminated or need for permanent
regimen change of at least two anti-TB drugs
because of:
•Lack of conversion by the end of the intensive
phasea; or
•Bacteriological reversion in the continuation
phase after conversion to negative; or
•Evidence of additional acquired resistance to
fluoroquinolones or second-line injectable
drugs; or
•Adverse drug reactions
Died A patient who dies for any reason during the
course of treatment
Lost to follow-up A patient whose treatment was interrupted for
2 consecutive months or more
Not evaluated A patient for whom no treatment outcome is
assigned (this includes cases “transferred out”
to another treatment unit and whose treatment
outcome is unknown)
Treatment success The sum of Cured and Treatment completed
aFor Treatment failed, lack of conversion by the end of the intensive phase
implies that the patient does not convert within the maximum duration of the
intensive phase applied by the programe. If no maximum duration is defined,
an 8 months cut-off is proposed. For regimens without a clear distinction
between intensive and continuation phases, a cut-off 8 months after the start
of treatment is suggested to determine when the criteria for Cured, Treatment
completed, and Treatment failed start to apply (for the investigational group,
6 months will be considered as an intensive phase)
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Additionally, NiX-TB (NCT02333799, phase III) is asses-
sing the safety and efficacy of a 6- or 9-month regimen
comprising bedaquiline, PA-824, and linezolid.
The present study, Treatment Shortening of MDR-TB
Using Existing and New Drugs (MDR-END), tests a 9–
12-month regimen of delamanid, linezolid, levofloxacin,
and pyrazinamide for MDR-TB patients without fluoro-
quinolone resistance. Delamanid and linezolid were selected
based on their bactericidal activities in a mouse model
[29, 30] and proven effectiveness in MDR-TB patients
[10, 17, 26, 31, 32], as well as on limited prior popula-
tion exposure. In addition, levofloxacin was selected
based on bactericidal activity [33], and it demonstrated
effectiveness in MDR-TB patients [34] and weaker QT
prolongation potential than moxifloxacin [35]. Finally,
pyrazinamide was included because of its bactericidal
sterilizing activity [15, 36] as well as its confirmed ef-
fectiveness in patients with MDR-TB [34].
Showing non-inferiority, although not superiority, of a
shorter regimen without an injectable to the conventional
regimen for MDR-TB treatment lasting 20–24months is
very important. Poor adherence to treatment is one of the
main causes of poor treatment outcome among patients
with MDR-TB, and it is strongly influenced by the long
treatment duration and use of an injectable, which can
cause ototoxicity or nephrotoxicity as well as pain at the
injection site. If our trial proves non-inferiority of the 9–
12-month fully oral regimen to the conventional 2-year
treatment including an injectable, then this shorter regi-
men could contribute to reducing MDR-TB globally by
improving patient adherence to treatment.
Trial status
Recruitment began at the first site in April 2016 and is
expected to be completed by April 2021.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 127 kb)
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